Finance

Will BioXcel’s New Strategy Reshape Agitation Treatment?
Organizational Governance Will BioXcel’s New Strategy Reshape Agitation Treatment?

The pharmaceutical industry currently faces a critical turning point as artificial intelligence transitions from a theoretical research tool into a practical engine for therapeutic discovery and clinical optimization. BioXcel Therapeutics stands at the center of this evolution, leveraging

Can Fiji Prioritize Quality Over Quantity in Medical Training?
Business Can Fiji Prioritize Quality Over Quantity in Medical Training?

The rapid expansion of Fiji’s healthcare workforce has reached a critical juncture where the sheer number of graduates may soon outpace the system’s ability to provide meaningful clinical mentorship. As the Fiji Medical Association (FMA) charts a new course under the leadership of Dr. Ronald Kumar,

How Can Healthcare Protect EHR From Rising Cyber Threats?
Technology How Can Healthcare Protect EHR From Rising Cyber Threats?

The silent transition from physical paper files to high-speed digital pixels has turned modern hospital servers into some of the most contested battlegrounds in the global landscape of information security. For decades, the primary focus of medical administration was the physical housing of

Why Are Poor Digital Transitions Costing the NHS Millions?
Data and Information Why Are Poor Digital Transitions Costing the NHS Millions?

The High Stakes of Digital Modernization in the National Health Service The push for universal Electronic Patient Record adoption has transformed the UK healthcare infrastructure into a massive laboratory for digital change. Across various medical trusts, the scale of these transformation projects

Can Value-Based Care Reform the Autism Treatment Crisis?
Care Can Value-Based Care Reform the Autism Treatment Crisis?

Redefining Success in the Face of a Growing Healthcare Challenge The staggering trajectory of national autism expenditures is rapidly approaching an annual half-trillion-dollar threshold that threatens to destabilize the broader healthcare ecosystem. This unsustainable surge in costs is driven

Will the $15B BMS-Hengrui Deal Reshape Global Pharma?
Organizational Governance Will the $15B BMS-Hengrui Deal Reshape Global Pharma?

A Landmark Collaboration in Biopharmaceutical Innovation When Bristol Myers Squibb finalized its massive fifteen billion dollar strategic alliance with Jiangsu Hengrui Pharmaceuticals, it signaled a fundamental reconfiguration of how the world's largest drugmakers source their future clinical

Loading

Subscribe to our weekly news digest

Keep up to date with the latest news and events

Paperplanes Paperplanes Paperplanes
Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later